Sanofi $SNY Stock Position Raised by Armistice Capital LLC

Armistice Capital LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 10.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 676,000 shares of the company’s stock after purchasing an additional 64,000 shares during the period. Armistice Capital LLC’s holdings in Sanofi were worth $32,759,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SNY. Guggenheim Capital LLC boosted its stake in shares of Sanofi by 30.2% during the 4th quarter. Guggenheim Capital LLC now owns 6,846 shares of the company’s stock worth $332,000 after acquiring an additional 1,586 shares in the last quarter. Bank OZK bought a new stake in shares of Sanofi during the 4th quarter worth about $208,000. Schonfeld Strategic Advisors LLC boosted its stake in shares of Sanofi by 175.3% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 112,966 shares of the company’s stock worth $5,474,000 after acquiring an additional 262,894 shares in the last quarter. DV Equities LLC bought a new stake in shares of Sanofi during the 4th quarter worth about $8,107,000. Finally, AQR Capital Management LLC boosted its stake in shares of Sanofi by 2.1% during the 4th quarter. AQR Capital Management LLC now owns 67,728 shares of the company’s stock worth $3,282,000 after acquiring an additional 1,406 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $42.50 on Thursday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $44.88 and its two-hundred day moving average is $46.39. The company has a market cap of $103.04 billion, a P/E ratio of 11.87, a P/E/G ratio of 1.09 and a beta of 0.34. Sanofi has a 12 month low of $42.28 and a 12 month high of $52.68.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were given a $2.4225 dividend. The ex-dividend date of this dividend was Monday, May 4th. This represents a yield of 559.0%. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is presently 49.16%.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent analyst reports. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a research note on Monday, April 20th. Morgan Stanley set a $52.00 price target on Sanofi in a research note on Friday, May 1st. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, Sanofi has an average rating of “Hold” and a consensus target price of $51.00.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.